CClinicalTrials.gg
CompletedNCT04207008iBDecideUpdated Feb 4, 2021

Trial of a Decision Support Intervention for Adolescents and Young Adults With Ulcerative Colitis

An interventional study of iBDecide Decision Support Application in Ulcerative Colitis, Pediatric, sponsored by Children's Hospital Medical Center, Cincinnati. Completed at 1 site in United States. Open to participants aged 14 Years to 25 Years. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
14 Years to 25 Years
Sex
All
01

Study summary

A web application decision support tool has been developed for adolescents and young adults (AYAs). The purpose of this pilot trial is to test the web application for adolescent and young adults (AYAs) with Ulcerative Colitis (UC). This research will assess acceptability, feasibility of the decision support intervention for AYA UC patients. Participants will be randomized to usual care or usual care plus the web application prior to an upcoming clinic visit in Gastroenterology. Participants will complete surveys one week after their clinic visit about decision making preferences and, for those in the intervention group, usability and acceptability of the web application.

Read the detailed description

The iBDecide app provides participants with electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.

Participants will be provided instructions over the phone or via email to download the iBDecide app on their personal smartphone approximately two weeks prior to the scheduled clinic visit. When possible they will download the app during the consent call and the research staff member will review features of the app with the participant. For those unable to download it while talking on the phone, a follow-up phone call will be scheduled to review the features. During the consenting phone call or at the clinic visit, a time will be scheduled to collect additional information via a brief telephone survey approximately one week after the clinic visit. Participants will be sent emails and an electronic calendar invitation to confirm their scheduled telephone interview.

02

Conditions studied

  • Ulcerative Colitis, Pediatric

Keywords

  • Adolescents and young adults
  • decision making
03

In context

Colitis

1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.

This study's enrollment of 42 is below the median of 60 across 771 interventional studies indexed under Colitis.

Browse Colitis studies →

Lead sponsor

Children's Hospital Medical Center, Cincinnati is the lead sponsor of 661 studies on the registry; 134 are open to participants now.

Of its 54 completed or terminated interventional studies of FDA-regulated products, 30 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • English speaking patients with Ulcerative Colitis that have an appointment at the CCHMC Gastroenterology clinic
  • 14-25 years of age
  • Treatment decision anticipated during clinic
  • Did not participate in usability testing for the iBDecide App
  • Has a smart phone that can download the iBDecide app

Exclusion criteria

Exclusion Criteria:

  • Unable to read or speak English
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    iBDecide App Decision-support Arm

    Participants will download the iBDecide app on their smartphone approximately two weeks prior to the scheduled clinic visit. Approximately one week after the clinic visit, survey data, along with demographic data will be collected from all participants via a brief telephone call. We will collect data on app use between installation and the clinic visit as well as in the 3 months following the clinic visit.

    Other: iBDecide Decision Support Application

  • No intervention
    Control Arm

    Control participants will not use the iBDecide app prior to their clinic visit. They will complete a brief telephone survey approximately one week from clinic visit.

Interventions

  • OtheriBDecide Decision Support Application

    The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.

06

What researchers measure

Primary outcomes

  1. Feasibility of intervention

    The extent to which this intervention impacts the flow of a clinic appointment, as measured by physician perception of visit length and efficiency.

    Time frame: At clinic visit

  2. Acceptability of intervention

    The extent to which patients and physicians feel the intervention is appropriate and useful. This is measured through adaptations of the System Usability Scale and the decision aid acceptability measure.

    Time frame: One week after clinic visit

Secondary outcomes

  1. Decisional conflict

    Measure of decisional uncertainty, assessed via Decisional Conflict Scale.

    Time frame: At clinic visit

  2. Perceived Shared Decision making

    Degree of shared decision-making the patient and physician each report, measured by the Shared Decision-Making Questionnaire-9 and Shared Decision-making Questionnaire 9-doc.

    Time frame: One week after clinic visit

  3. Decision preference congruence

    Extent to which the patients' role in the decision process matched their preferred role, measured via the Control Preference Scale.

    Time frame: One week after clinic visit

07

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
08

References and documents

Publications

  • Matula KA, Minar P, Daraiseh NM, Lin L, Recker M, Lipstein EA. Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. Health Expect. 2022 Dec;25(6):3105-3113. doi: 10.1111/hex.13618. Epub 2022 Sep 26. PubMed 36161973 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04207008
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Responsible party
Ellen A. Lipstein MD, MPH (Associate Professor, Children's Hospital Medical Center, Cincinnati) — Principal investigator
First posted
Dec 20, 2019
Start date
Feb 7, 2020
Primary completion
Oct 23, 2020
Completion
Jan 23, 2021
Last update
Feb 4, 2021

Study contacts

Ellen Lipstein, MD, MPH
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion